Table 4.
Descriptive analysis of the included studies.
| Study characteristics | Study attributes | Number of studies (%) | Study ID |
|---|---|---|---|
| Year of Publication | 2020 | 2 (4%) | 31,32 |
| 2021 | 24 (52%) | 33–56 | |
| 2022 | 20 (43%) | 57–76 | |
| Geographical Coverage | National Level | 17 (37%) | 31,40–41, 44–45, 47, 49, 51–52, 55, 58–59, 63, 65, 70, 73–74 |
| Multi-state Level | 5 (11%) | 39, 54, 71, 75–76 | |
| State Level | 22 (48%) | 32–35, 37–38, 42–43, 46, 48, 50, 53, 57, 60–62, 64, 66–69, 72 | |
| District Level | 2 (4%) | 36, 56 | |
| Mode of data collection | Online | 26 (57%) | 31–34, 37, 39–41, 44–45, 47, 49–55, 58–59, 63, 65, 67–69, 72 |
| Off-line | 18 (39%) | 35–36, 38, 42–43, 48, 56–57, 60–62, 64, 66, 71, 73–76 | |
| Dual mode | 2 (4%) | 46, 70 | |
| Study design | Cross-Sectional | 43 (93%) | 31–35, 38, 40–76 |
| Longitudinal | 3 (7%) | 36–37, 39 | |
| Survey duration | ≤1 Month | 27 (59%) | 31, 34, 37–38, 40–41, 43–45, 48, 50–53, 55–57, 60–63, 67–69, 71–73 |
| >1 & ≤ 2 Month | 9 (20%) | 32–33, 35, 54, 58–59, 64–65, 75 | |
| ≥3 Month | 5 (11%) | 46, 66, 70, 74, 76 | |
| Separate Rounds (1 Month Each) | 2 (4%) | 36, 39 | |
| Not mentioned | 3 (7%) | 42, 47, 49 | |
| Age | 18 years and above | 34 (74%) | 31, 33, 35–37, 40–46, 48–50, 52–59, 62–68, 70, 72–73, 75 |
| Age range mentioned | 4 (9%) | 38, 51, 74, 76 | |
| Mean age mentioned | 5 (11%) | 34, 39, 60–61, 69 | |
| Not mentioned | 3 (7%) | 32, 47, 71 | |
| Sample Size | Sum | 65551 | - |
| Average | 1425 | - | |
| <1000 | 28 (61%) | 31, 34–38, 41–43, 46–50, 52–54, 56, 59–61, 63, 67–69, 72, 75–76 | |
| 1000–2000 | 9 (20%) | 32–33, 40, 45, 55, 58, 65–66, 71 | |
| 2000–3000 | 7 (15%) | 39, 44,51,62, 70, 73–74 | |
| >3000 | 2 (4%) | 57, 64 | |
| Gender | Female | 35906 (55%) | - |
| Male | 25723 (39%) | - | |
| Gender distribution is not mentioned | 6 (13%) | 32, 41, 43, 47–48, 71 | |
| Target Population | General | 37 (80%) | 31–36, 39–42, 44–59, 63–68, 70–73, 75 |
| Vulnerable (Patients with HIV; Psychiatric disorders; systemic autoimmune rheumatic disease; individuals with co-morbidities; multiple myeloma and AL amyloidosis | 6 (13%) | 37–38, 4, 61–62, 76 | |
| Pregnant Women | 3 (7%) | 60, 69, 74 | |
| Vaccine Outcomes | Vaccine acceptance | 21 (46%) | 32–35, 43–46, 51–57, 63–64, 66, 70–71, 73 |
| Vaccine hesitancy | 16 (35%) | 31, 36–40, 42, 47, 49–50, 60–62, 72, 74–75 | |
| Vaccine willingness/awareness | 8 (17%) | 41, 48, 58–59,65, 67–69 | |
| Vaccine uptake | 1 (2%) | 76 | |
| Key Considerations | Survey duration – not mentioned | 3 (7%) | 42, 47, 49 |
| Age distribution – not mentioned | 3 (7%) | 32, 47, 71 | |
| Gender distribution – not mentioned | 6 (13%) | 32, 41, 43, 47–48, 71 |